TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28704286

Group type: EXPERIMENTAL
Intervention: Force Feedback (FFB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No Force Feedback (Control)
Number of subjects: 101
Study: 25646363

Group type: EXPERIMENTAL
Intervention: PLB fixation at 0° (P0)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PLB fixation at 20° (P20)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PLB fixation at 45° (P45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison of P20 vs P45
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison of P0 vs P45
Number of subjects: 90
Study: 24326980

Group type: EXPERIMENTAL
Intervention: 150 μM piperine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 mM piperine
Number of subjects: 40
Study: 22119244

Group type: EXPERIMENTAL
Intervention: K-134 50 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: K-134 100 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: K-134
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: K-134 and cilostazol
Number of subjects: 402
Study: 19221402

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (milked group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study: 17503880

Group type: EXPERIMENTAL
Intervention: Next generation drug-eluting stents (including sirolimus analogs, biodegradable and bioabsorbable materials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reservoir stents with different drug release profiles
Number of subjects: 0
Study: 15489844

Group type: EXPERIMENTAL
Intervention: Standard therapy plus tianeptine 37.5 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 40
Study: 16123227

Group type: EXPERIMENTAL
Intervention: Clonidine (15 mg/week for 8 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10364994

Group type: EXPERIMENTAL
Intervention: Auditory Evoked Potential (AEP) index
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 95% Spectral Edge Frequency (SEF)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Median Frequency (MF)
Number of subjects: 46
Study: 8880042

Group type: EXPERIMENTAL
Intervention: High fat snack foods after low energy lunch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High fat snack foods after high energy lunch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High sucrose snack foods after low energy lunch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High sucrose snack foods after high energy lunch
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low energy lunch followed by high sucrose snack
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High fat snacks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test day energy intake excluding alcoholic drinks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Day following study day energy intake
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Appetite ratings
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High fat snacks pleasantness rating
Number of subjects: 20
Study: 1994861

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MRI (Proton density and STIR sequences)
Number of subjects: 12
Study: 6594713

Group type: EXPERIMENTAL
Intervention: 20 mg naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31141497

Group type: EXPERIMENTAL
Intervention: Nitrate-rich salad and citrulline drink (520mg nitrate and 6g citrulline)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study: 27937084

Group type: EXPERIMENTAL
Intervention: Rebamipide (REB) ophthalmic suspension
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diquafosol (DQS) ophthalmic solution
Number of subjects: 40
Study: 26785125

Group type: EXPERIMENTAL
Intervention: Self-reported rating of adherence
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Self-reported frequency of doses taken
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Self-reported percentage of doses taken
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Unannounced pill counts (UPC)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Electronic monitoring
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Plasma tenofovir levels (SSDD; ≥40 ng/ml)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Self-reported rating
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Self-reported frequency
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Self-reported percentage
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Correlation among self-reported measures
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Correlation between self-reported measures and UPC
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Correlation between self-reported measures and electronic monitoring
Number of subjects: 1147
Study: 24504688

Group type: EXPERIMENTAL
Intervention: Metoclopramide (7 mg) plus dimeticone (40 mg) and pepsin (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional metoclopramide capsule (7 mg)
Number of subjects: 0
Study: 21750253

Group type: EXPERIMENTAL
Intervention: QUI (quinapril) 40 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: QUI + ALA (quinapril 40 mg/d + α-lipoic acid 600 mg/d)
Number of subjects: 40
Study: 19218830

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Continuation phase (nonrelapsing subjects)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Continuation phase (relapsing subjects)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Depressive component scores at entry into continuation
Number of subjects: 316
Study: 17445589

Group type: EXPERIMENTAL
Intervention: Alendronate 35 mg/wk for 6 months (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 50
Study: 16198251

Group type: EXPERIMENTAL
Intervention: β-blocker
Number of subjects: 800
Study: 12546524

Group type: EXPERIMENTAL
Intervention: 1000 IE epoetin‐beta
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5000 IE epoetin‐beta
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Quality of life measurement (EORTC QLQ‐C30)
Number of subjects: 180
Study: 9803777

Group type: EXPERIMENTAL
Intervention: Low-protein diet with hypercaloric supplement (Suplena)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (same low-protein diet, 0.6 g protein/kg/day)
Number of subjects: 33
Study: 7644095

Group type: EXPERIMENTAL
Intervention: Absorbable staples in vaginal cuff closure
Number of subjects: 104

Group type: COMPARATOR
Intervention: Classical abdominal hysterectomy
Number of subjects: 104
Study: 30993795

Group type: EXPERIMENTAL
Intervention: Titanium abutment‐supported porcelain fused to metal (PFM) restorations
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Zirconium abutment‐supported ceramic restorations
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (matched in gender and age)
Number of subjects: 170
Study: 28182279

Group type: EXPERIMENTAL
Intervention: AMIO + RAN (1 g oral dose)
Number of subjects: 173

Group type: COMPARATOR
Intervention: AMIO (5 mg/kg loading dose followed by 50 mg/h)
Number of subjects: 173
Study: 26731976

Group type: EXPERIMENTAL
Intervention: Mineral waters, peloids, and calcipotriol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcipotriol alone
Number of subjects: 60
Study: 23455699

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined spinal and general anesthesia
Number of subjects: 69
Study: 21714757

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg) administered daily for four weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administered daily for four weeks
Number of subjects: 14
Study: 19781325

Group type: EXPERIMENTAL
Intervention: Hyperoxygenated solution (HO group, n = 109)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal saline solution (NO group, n = 115)
Number of subjects: 5
Study: 16475478

Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD) group
Number of subjects: 173

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 173
Study: 14559126

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 87339
Study: 11084156

Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost of hip protectors
Number of subjects: 0
Study: 9392326

Group type: EXPERIMENTAL
Intervention: Balloon sampler
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Sponge sampler
Number of subjects: 439
Study: 8513722

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 84

Group type: COMPARATOR
Intervention: H2-blockers
Number of subjects: 84
Study: 3541602

Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg two times daily to maximum of 20 mg per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Captopril (25 mg three times daily to a maximum of 450 mg per day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prazosin + Polythiazide (if diastolic blood pressure not controlled)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Captopril + Polythiazide (if diastolic blood pressure not controlled)
Number of subjects: 31
Study: 31593299

Group type: EXPERIMENTAL
Intervention: 5 mL lidocaine 2% diluted in 15 mL normal saline
Number of subjects: 260

Group type: COMPARATOR
Intervention: 20 mL normal saline alone
Number of subjects: 260
Study: 30602688

Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (5-6 targets met)
Number of subjects: 874
Study: 27649232

Group type: EXPERIMENTAL
Intervention: Nutritional intervention combined with health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 0
Study: 24912663

Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22034645

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prudent diet (PD)
Number of subjects: 40
Study: 20386132

Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM) 8 grams
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 19293592

Group type: EXPERIMENTAL
Intervention: Dual blockade with ACE inhibitor and angiotensin II receptor blocker
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no dual blockade)
Number of subjects: 93
Study: 16437672

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g twice a day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12608523

Group type: EXPERIMENTAL
Intervention: Intentional weight loss (IWL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medically recommended methods for IWL
Number of subjects: 0
Study: 10496437

Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 8 mg once daily
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 16 mg once daily
Number of subjects: 217

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: candesartan cilexetil
Number of subjects: 217
Study: 8545570

Group type: EXPERIMENTAL
Intervention: Photocoagulation
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Baseline accommodative amplitude
Number of subjects: 1058
Study: 1721575

Group type: EXPERIMENTAL
Intervention: Arithmetic task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mental rotation task
Number of subjects: 0
Study: 7129643

Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 60
Study: 31699069

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) combined with rehabilitation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Rehabilitation only (control group)
Number of subjects: 119
Study: 30588956

Group type: EXPERIMENTAL
Intervention: Advagraf (once-daily tacrolimus)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Prograf (twice-daily tacrolimus)
Number of subjects: 99
Study: 26767411

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (SC) 50 mg capsules, maximum 150 mg, given eight hourly during labour
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo capsules given eight hourly during labour
Number of subjects: 100
Study: 24694207

Group type: EXPERIMENTAL
Intervention: Self-Management education for epilepsy (SMILE (UK) course with treatment as usual)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 428
Study: 22316315

Group type: EXPERIMENTAL
Intervention: Vaginal gel containing isoflavones, Lactobacillus sporogenes, Calendula officinalis extract and lactic acid (Estromineral Gel, Rottapharm‐Madaus) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Number of subjects: 186

Group type: COMPARATOR
Intervention: No topical treatment (NT) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Number of subjects: 186
Study: 20807792

Group type: EXPERIMENTAL
Intervention: 20 mm capsazepine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mm l‐NAME
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined 20 mm capsazepine + 10 mm l‐NAME
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle control (90% propylene glycol + 10% lactated Ringer solution)
Number of subjects: 10
Study: 16097707

Group type: COMPARATOR
Intervention: antibacterial therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: antibacterial therapy + alpha-adrenoblockers
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: antibacterial therapy + transrectal laser and magnetic physiotherapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: antibacterial therapy + alpha-adrenoblockers + transrectal laser and magnetic physiotherapy
Number of subjects: 69
Study: 11849155

Group type: EXPERIMENTAL
Intervention: Allogeneic human tumour cell vaccine with Mycobacterium vaccae (SRL‐172)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 10399410

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGI) - Vitremer
Number of subjects: 2

Group type: COMPARATOR
Intervention: Silver-reinforced glass ionomer (cermet) - Ketac-Silver
Number of subjects: 2
Study: 7581527

Group type: EXPERIMENTAL
Intervention: BCG plus recombinant alpha-interferon 2b
Number of subjects: 36

Group type: COMPARATOR
Intervention: BCG full dose
Number of subjects: 36
Study: 2184287

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (5 mg/kg over 20 minutes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral quinidine (400 mg immediately and 400 mg in 4 hours)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral quinidine
Number of subjects: 80
Study: 6115246

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (200 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mebendazole (2 g/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg per week)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mebendazole plus Levamisole
Number of subjects: 40
Study: 28917678

Group type: EXPERIMENTAL
Intervention: OFDI-guided PCI
Number of subjects: 106

Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 106
Study: 27191247

Group type: EXPERIMENTAL
Intervention: 200 mg/day of red grape seed extract (RGSE) for eight weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24723314

Group type: EXPERIMENTAL
Intervention: Pharmacological blockade of α‐adrenergic‐, muscarinic‐, and calcium channel‐mediated mechanisms
Number of subjects: 43
Study: 24355447

Group type: EXPERIMENTAL
Intervention: Direct access to chest CT before chest-physician evaluation
Number of subjects: 493

Group type: COMPARATOR
Intervention: Control group (standard pathway)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Direct access to chest CT
Number of subjects: 493
Study: 21208095

Group type: EXPERIMENTAL
Intervention: MCT and protein-enriched enteral nutrition (Group I)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Isocaloric enteral nutrition (Group II)
Number of subjects: 229
Study: 18030411

Group type: EXPERIMENTAL
Intervention: Postoperative multidisciplinary, multifactorial fall-prevention program including staff education, systematic assessment and treatment of fall risk factors, vitamin D and calcium supplementation
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study: 16816303

Group type: EXPERIMENTAL
Intervention: Risperidone or Haloperidol (flexible dose, median treatment length 206 days)
Number of subjects: 530
Study: 12816293

Group type: EXPERIMENTAL
Intervention: Herbal-based mouthrinse with oral irrigator
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Conventional mouthwash with oral irrigator
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional mouthwash without subgingival irrigation
Number of subjects: 89
Study: 10854652

Group type: EXPERIMENTAL
Intervention: Interferon-beta1a (Avonex)
Number of subjects: 0
Study: 9120313

Group type: EXPERIMENTAL
Intervention: Recombinant envelope proteins (Env, gp120, and gp160)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live virus or recombinant protein immunogen
Number of subjects: 0
Study: 1555906

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3890538

Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 74

Group type: COMPARATOR
Intervention: gentamicin and clindamycin
Number of subjects: 74
Study: 29793353

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 150

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 150
Study: 30048547

Group type: EXPERIMENTAL
Intervention: Oligofructose (OF) 7g twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maltodextrin (MD) 7g twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 37
Study: 27235528

Group type: EXPERIMENTAL
Intervention: Mobi-C implant
Number of subjects: 99

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 99
Study: 24793409

Group type: EXPERIMENTAL
Intervention: Segmental impedance spectroscopy with combined multiple electrodes added to the 15 lead ECG
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Segmental impedance spectroscopy
Number of subjects: 119
Study: 23406605

Group type: EXPERIMENTAL
Intervention: Absorbable hyaluronan hydrogel
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no absorbable hyaluronan hydrogel)
Number of subjects: 55
Study: 20653437

Group type: EXPERIMENTAL
Intervention: Early healing (14 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Delayed healing (27 weeks)
Number of subjects: 33
Study: 18959605

Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 4385

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 4385
Study: 15992789

Group type: EXPERIMENTAL
Intervention: PTCA therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-therapy patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 35
Study: 12847783

Group type: EXPERIMENTAL
Intervention: MMPI-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAI
Number of subjects: 0
Study: 10231223

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (N‐acetylcysteine, selenium, vitamins C and E) for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no antioxidant therapy)
Number of subjects: 18
Study: 8897027

Group type: EXPERIMENTAL
Intervention: Incremental exercise protocol (cycling for three periods of 6 min at power outputs of 55%, 70%, and 85% VO2max)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Incremental exercise protocol
Number of subjects: 64
Study: 1986895

Group type: EXPERIMENTAL
Intervention: EVLW‐SI (Single Indicator)
Number of subjects: 18

Group type: COMPARATOR
Intervention: EVLW‐DI (Double Indicator)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: COfem‐si (Single Indicator Cardiac Output)
Number of subjects: 18

Group type: COMPARATOR
Intervention: COfem‐di (Double Indicator Cardiac Output)
Number of subjects: 18
Study: 6363154

Group type: EXPERIMENTAL
Intervention: Cotrimazine (sulfadiazine 900 mg + trimethoprim 300 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ampicillin 2 g daily
Number of subjects: 30
Study: 31193330

Group type: EXPERIMENTAL
Intervention: HVGIC/CHX
Number of subjects: 100

Group type: COMPARATOR
Intervention: HVGIC
Number of subjects: 100
Study: 30369351

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 40
Study: 27266229

Group type: EXPERIMENTAL
Intervention: Plai cream (n = 70 patients)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (n = 70 patients)
Number of subjects: 140
Study: 25208616

Group type: EXPERIMENTAL
Intervention: Target group treated with specific techniques added to conventional physiotherapy for stroke
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group treated with conventional physiotherapy for stroke
Number of subjects: 13
Study: 23088168

Group type: COMPARATOR
Intervention: Pharmacist management alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pharmacist management plus HP support
Number of subjects: 300